Post-Orgasmic Illness Syndrome
POIS - Post-Ejaculatory Flu-Like Syndrome
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved therapy; diagnosis is clinical
Reference only. Not medical advice.
What can go wrong
Evidence is limited to case reports and small series; the hypersensitivity hypothesis, though supported by skin testing, is not definitively proven. Diagnosis remains clinical (Waldinger's criteria) after excluding mimics. Hyposensitization with diluted autologous semen is investigational and must be physician-directed.
This is something to take to a clinician. The Atlas can tell you what is known about post-orgasmic illness syndrome in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Post-orgasmic illness syndrome is a rare, under-recognized condition of clustered flu-like, neurologic, cognitive, and allergic-type symptoms beginning minutes to hours after ejaculation and lasting days. First described by Waldinger and Schweitzer in 2002, the leading hypothesis is a type I/IV hypersensitivity reaction to a man's own semen, supported by positive autologous-semen skin testing and reported responses to hyposensitization. This entry covers POIS in depth alongside dysorgasmia.
Debilitating flu-like symptoms triggered by ejaculation - real, rare, and poorly understood.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Waldinger proposed a hypersensitivity reaction to peptides from semen or urethral mucosa. In 2011 his group performed intradermal autologous-semen skin tests in 33 men with POIS and reported positive reactions, supporting an immunologic mechanism. Alternative hypotheses include neuroendocrine dysregulation, opioid-withdrawal-like states, and hypogonadism.
What people get wrong
Often saidPOIS is purely psychological or made up
ActuallyPositive autologous-semen skin testing and reported hyposensitization responses point to a real, likely immunologic mechanism - though the evidence base remains small.
Who profits, and who pushes back
Postorgasmic Illness Syndrome: An Update (Sex Med Rev)
Despite the leading immunologic hypothesis, there is no hard proof of an autologous-semen allergy, and treatment remains empirical.
At a glance
- First described
- Waldinger & Schweitzer, 2002
- Onset after ejaculation
- Minutes to hours
- Duration
- Days
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Post-Orgasmic Illness Syndrome. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Waldinger & Schweitzer, initial description of POIS2002
First defined the syndrome and proposed semen hypersensitivity
Waldinger et al., autologous-semen skin testing in 33 men2011
Reported positive intradermal reactions supporting an immunologic mechanism
hCG and hypogonadal-rescue case reports (PMC12535417)2020s
Described hormonal contributors and responses in selected patients